Global Media First Drive of G700: A Comprehensive Validation of GAIA Hybrid Off-Road Architecture 
Scandium International Mining Announces Exercise of Options by Chief Executive Officer and Chief Financial Officer 
Universal Digital Announces Financing of up to $50 Million Aggregate Principal Amount of Convertible Debentures 
HEALWELL Files Amended Business Acquisition Report 
Universal Digital Inc. Announces Marketing Agreement with Plutus Invest & Consulting GmbH CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a…
Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and “BB” Rating from Egan-Jones
NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused…
Primo Nutraceuticals Inc. Corporate Update
VANCOUVER, British Columbia, April 14, 2021 (GLOBE NEWSWIRE) — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC:…
Harrow Health Announces Preliminary First Quarter 2021 Financial Results
NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused…
Emerging Markets Report: A Moment for the Mushroom
Core One Labs Looking to Compete in Psylocibin with a Proprietary Offering at a Fraction…
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical…
Cosmos Holdings Launches Proprietary King Eros and Queen Venus Supplements for Enhanced Libido
Sky Premium Life King Eros and Queen Venus Supplements Sky Premium Life King Eros and…
Alimera Sciences Receives $20 Million From Ocumension Therapeutics
Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to…
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the…
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a…
CohBar to Present at the Mitochondria-Targeted Drug Development Summit
MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
CorMedix Has Meeting With FDA on DefenCath Catheter Lock Solution NDA
BERKELEY HEIGHTS, N.J., April 14, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Agenus Doses First Cancer Patient with iNKT Cell Therapy
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq:…
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
– Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations –…
Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
PRESS RELEASE April 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price…
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 14, 2021 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is…
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in…